Stockscreener 앱 받기
4.831
6.14%
0.271
전일 마감가:
$4.56
열려 있는:
$4.56
하루 거래량:
142.49K
Relative Volume:
0.58
시가총액:
$103.55M
수익:
$155.00K
순이익/손실:
$-30.01M
주가수익비율:
-3.1783
EPS:
-1.52
순현금흐름:
$-11.98M
1주 성능:
-11.03%
1개월 성능:
-6.56%
6개월 성능:
-54.17%
1년 성능:
-38.81%
1일 변동 폭
$4.47
$4.86
1주일 범위
$4.45
$5.34
52주 변동 폭
$4.45
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
명칭
Inmune Bio Inc
전화
(858) 964-3720
주소
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
INMB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| INMB | 4.83 | 103.55M | 155.00K | -30.01M | -11.98M | -1.52 |
| VRTX | 450.67 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.51 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-05-24 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-21 | 개시 | B. Riley Securities | Buy |
| 2021-01-22 | 재확인 | Maxim Group | Buy |
| 2020-09-01 | 개시 | BTIG Research | Buy |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
모두보기
Inmune Bio Inc 주식(INMB)의 최신 뉴스
Scotiabank Initiates Coverage of INmune Bio (INMB) with Sector Outperform Recommendation - MSN
INmune Bio stock hits 52-week low at $4.76 amid market challenges - Investing.com
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
Inmune Bio Emerges as Biotech Innovator in 2023 - TipRanks
Learn to Evaluate (INMB) using the Charts - Stock Traders Daily
INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript - MSN
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance UK
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Earnings call: INmune Bio Q3 2024 results show progress in clinical trials - Investing.com
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update - The Manila Times
Inmune Bio Reports Increased Losses Amid Financing Efforts - TipRanks
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
INmune Bio Q3 2024 Earnings Preview - MSN
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6% - MarketBeat
INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB - The Manila Times
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance
INmune Bio (INMB) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
INmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System Diseases - MarketWatch
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination - The Manila Times
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 - The Manila Times
Insider Stock Buying Reaches US$951.2k On INmune Bio - Yahoo Finance
Alliance Global Partners Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World
(INMB) Technical Data - Stock Traders Daily
INmune Bio stock hits 52-week low at $4.8 amid market challenges - Investing.com
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Decrease in Short Interest - MarketBeat
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit - The Manila Times
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs By GuruFocus - Investing.com Canada
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs - Yahoo Finance
Where are the Opportunities in (INMB) - Stock Traders Daily
Insider Buying: CFO and 10% Owner David Moss Acquires Shares of INmune Bio Inc (INMB) - GuruFocus.com
INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Buys 10,000 Shares - Defense World
Inmune Bio CFO buys $52,868 in company stock - Investing.com India
Inmune Bio CFO buys $52,868 in company stock By Investing.com - Investing.com South Africa
Analytical Overview: INmune Bio Inc (INMB)’s Ratios Tell a Financial Story - The Dwinnex
INmune Bio Inc [INMB] Investment Guide: What You Need to Know - Knox Daily
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal (NASDAQ:INMB) - Seeking Alpha
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
CVI Holdings LLC Takes $5.26 Million Position in INmune Bio, Inc. (NASDAQ:INMB) - MarketBeat
Raymond James Initiates Coverage of INmune Bio (INMB) with Outperform Recommendation - MSN
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - Defense World
INmune Bio reports progress in prostate cancer trial By Investing.com - Investing.com Australia
INmune Bio reports progress in prostate cancer trial - Investing.com
Inmune Bio Inc (INMB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):